EU wants to withdraw all dextropropoxyphene products
This article was originally published in Scrip
All marketing authorisations for dextropropoxyphene-containing products should be withdrawn in the EU because of the risk of intentional or accidental overdose, the EU's CHMP has recommended. The risk of overdosing only became evident when data from national poison centres and mortality statistics throughout the EU were analysed in depth, the committee adds.
You may also be interested in...
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
An ultra-fast-acting allergy immunotherapy to induce tolerance to house dust mites is being sought in a collaboration between two Swiss biotechs, Anergis and Virometix.
Emerging Company Profile: Austria’s OncoOne could have an anticancer biologic which targets oxidized macrophage migration inhibitor factor ready for the clinic in around two years.